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Editorial on the Research Topic
Controversies in the Local Management of Lung Cancer
At the time we agreed to edit this special edition of Frontiers in early 2017, the immunotherapy 
revolution was already established in the second-line treatment of metastatic non-small cell lung 
cancer (NSCLC) (1–4) and even to a select group of patients (those whose tumor cells expressed 
PD-L1 of ≥50%) (5) in the first-line treatment of metastatic disease. We felt that the summarization 
and understanding of the strengths and benefits of our local modalities were needed prior to the 
possible integration of immunotherapy into the treatment paradigms of Stages I–III NSCLC and 
small cell lung cancer (SCLC).
Three of this issue’s 10 article deal with the controversial topic of neo-adjuvant treatment prior 
to surgery in the management of Stage III lung cancer from the prospective of a multi-disciplinary 
team (Lewis et  al.), a Radiation Oncologist (Sher), and a Thoracic Surgical group (Van et  al.). 
Although no definitive management strategy was recommended as “the way” to manage Stage 
III NSCLC, each article does a great job of reviewing the current literature, while offering its own 
unique perspective. The article by Van et al. additionally discusses the rarely investigated topic of 
salvage surgery.
Four articles dealt with unconventional and/or innovative uses of radiation. Ohri provides a 
provocative article concerning dose escalation as well as dose de-escalation. Although the idea of 
dose de-escalation is unpalatable to most Radiation Oncologists, this idea may be considered to 
be prescient because of the now described synergism between concomitant cytotoxic therapy and 
immunotherapy in patients with metastatic non-squamous cell NSCLC (6). Kumar et al. offer a 
pioneering approach to the treatment of Stage III NSCLC which they have labeled quadmodality 
therapy (concurrent chemo/radiation followed by a stereotactic boost to residual sites of disease, 
followed by immunotherapy) for the more aggressive treatment of locally advanced lung cancer 
(Kumar et  al.). Both studies, offer different approaches to the hopefully successful integration 
of immunotherapy with standard chemo/radiation in the near future. Bergsma et al. discuss the 
rationale and increasingly strong evidence for administering stereotactic body radiation therapy 
(SBRT) in patients with oligometastatic NSCLC (Bergsma et al.). The work of these investigators 
and others have led to the NRG LU002 trial that will be investigating the role of SBRT for patients 
with three or fewer sites of remaining extracranial disease after chemotherapy. Chun et al. have 
provided a nice review article on heavy ion therapy in the management of NSCLC. Although 
the recently published prospective randomized trial of passive scattering proton radiation vs 
intensity-modulated radiation did not reveal any benefit from proton therapy in terms of local 
failure, radiation pneumonitis, and lung dosimetry, protons resulted in lower heart doses despite 
larger having larger gross tumor volumes in that trial arm (7). Because heart dose was a strong 
determinant of overall survival in RTOG 0167’s failure to improve outcomes by radiation dose 
escalation (8), it is hoped that the Bragg–Peak associated with heavy ion therapy will be proven to 
offer improved local control while limiting normal tissue damage.
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The articles by Bloom et  al. and Jeremic et  al. remind the 
readers of Frontiers how important local management is to the 
outcomes of SCLC. Bloom et al. offer a comprehensive review of 
the literature concerning prophylactic cranial irradiation (PCI) 
in the management of surgically resectable SCLC. Because the 
incidence of early-stage SCLC is increasing (9), the review of this 
topic is very important. Although the authors could not reach a 
definitive conclusion regarding PCI, it is hoped that NRG CC003 
demonstrates that hippocampal sparing allows for effective PCI 
while limiting harmful neurocognitive sequelae and makes the 
decision to administer PCI in surgically resectable SCLC an easier 
one. Jeremic et al. comprehensively review consolidative thoracic 
radiation in the management of extensive stage SCLC from their 
pioneering work published in 1999 (10) to the more recent work 
of Slotman et al. (11). They also discuss the potential merits of dif-
ferent radiation fractionation regimens and the use of sequential 
vs concomitant chemo/radiation regimens. Furthermore, the 
authors provide a timely update of the conflicting data (12, 13) 
in regards to the use of PCI for the treatment of patients with 
extensive stage SCLC.
Although there are no articles in this edition concerning the 
benefits and risk of SBRT in comparison to surgical resection 
for patients with Stage I NSCLC, and past retrospective studies 
(14, 15) and one small publication of prospective data (16) have 
suggested equivalency, it is hoped that future studies may shed 
light on proper patient selection for either of these very effec-
tive techniques. Until then, the article by Varlotto et  al. sheds 
needed light on how psychosocial aspects can adversely affect 
the outcomes of surgically resected NSCLC. These authors dem-
onstrated that not being married and having insurance resulted 
in lower overall survival/lung cancer-specific survival, increased 
90-day mortality and a higher incidence of positive nodes upon 
resection.
During the last decade surgical treatment of lung cancer 
changed deeply thanks to the large diffusion of minimally 
invasive approaches that become the standard approach for 
early-stage lung cancer (17). Thanks to the introduction of 
robotic technology, more recently, even selected patients with 
more advanced disease, even after induction treatment for N2 
involvement, have been approached with minimally invasive 
robotic surgery to reduce surgical trauma, a very important goal 
in patients with already increased fragility due to systemic treat-
ment (18). Recent publications showed that robotic approach 
was safe and effective in this subgroup of patients, paving the 
way to potential changes in the indications of surgical resection 
in stage III patients, and a rethinking of the better timing for 
systemic and local treatment (19) with potential advantages 
to propose minimally invasive surgery upfront for N2 single 
station disease.
Since our initial agreement to edit this special edition, immu-
notherapy has continued to radically change the lung cancer 
landscape. A press release from Merck on April 9, 2018 concern-
ing Keynote-042 demonstrated a superior OS for pembrolizumab 
(a PD-1 inhibitor) as compared to platinum-based chemotherapy 
in the first-line setting. The benefit was shown in a population 
of patients with PD-L1 of ≥1% which means that the majority 
of patients presenting with metastatic NSCLC can benefit from 
immunotherapy alone as their initial treatment. Furthermore, 
Keynote 189 (Van et al.) noted an improved overall survival and 
progression-free survival using combined immunotherapy (pem-
bolizumab) and chemotherapy as compared to chemotherapy 
alone. Additionally, consolidative durvalumab (a PD-L1 inhibi-
tor) has shown an impressive progression-free survival benefit 
in patients with stage III lung cancer after the completion of 
concurrent chemo/radiation (20). We feel that the articles in this 
special edition can help the readers of Frontiers better understand 
the strength and limitations of our existing local therapies so that 
we can better understand how to incorporate immunotherapy in 
the management of Stage I–III NSCLC and SCLC.
We are very grateful to the tremendous efforts of the fellow 
authors, the reviewers, and staff at Frontiers for making this 
special edition possible.
aUtHor CoNtriBUtioNS
GV and JV both wrote this article.
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